Unlocking the Value of Patient Self-Monitoring Technologies: A Multi-Country Framework to Calibrate Payer and HTA Coverage and Reimbursement Considerations with Innovation [0.03%]
基于创新的患者自我监测技术的 payer 和 hta 付款人覆盖和补偿标准多国校准框架
James K Karichu,Shafie Kamaruddin,Pinar Bilir et al.
James K Karichu et al.
Background: Patient self-monitoring (PSM) is emerging as an innovative modality for chronic disease management. While PSM technologies are established in therapeutic areas including diabetes and cardiovascular diseases, c...
Projected Reduction of Diabetes- and Obesity-Related Complication Risks Following the 12-Week Weight-Loss Phase of the RESET Study [0.03%]
RESET研究减重阶段预期对糖尿病和肥胖相关并发症风险的改善作用
Bjoern Schwander,Kirk W Kerr,Ricardo Rueda et al.
Bjoern Schwander et al.
Background: Type 2 diabetes (T2D) and obesity increase individuals' risk of microvascular and macrovascular complications, which may increase healthcare costs. The RESET program combined low-calorie diet using diabetes-sp...
Real-World Completion of Multitarget Stool DNA Testing Among Texas Medicare Beneficiaries: Associations With Payer Type, Digital Outreach, and Social Vulnerability [0.03%]
德克萨斯州医疗保险受益人的多靶点粪便DNA检测真实世界完成率与支付方式、数字宣传和社交脆弱性的关联性分析
Timothy Ritter,Shrey Gohil,Betthany Thomas et al.
Timothy Ritter et al.
Background: Colorectal cancer is a leading cause of cancer-related morbidity and mortality in the United States; however, a substantial proportion of eligible adults do not complete screening. ...
Cognitive Behavioral Therapy in Early Intervention for Psychosis: A Cost-Effectiveness Analysis [0.03%]
针对早期精神分裂症的认知行为疗法的成本效益分析
Maximilian Duckworth,Sofia Venturini,Andres Roman-Urrestarazu
Maximilian Duckworth
Background: Early intervention for psychosis (EIP) is a multidisciplinary service that treats individuals experiencing early psychosis. Treatment often consists of pharmacotherapy and cognitive behavioral therapy for psyc...
Patterns in Attribute Selection and Development Reporting in Patient Preference Studies Between 2007-2024: A Systematic Literature Review [0.03%]
2007-2024年患者偏好研究中属性选择和发展报告的模式：系统文献回顾
Siu Hing Lo,Rebekah Hall,Joy Wong et al.
Siu Hing Lo et al.
Background: Discrete choice experiments (DCE) are commonly used for understanding patient preferences. However, their validity relies upon appropriate attribute selection and development. The present review aimed to ident...
Peripheral T-cell Lymphoma in Japan: Real-World Patient Characteristics, Treatment Patterns, Healthcare Resource Utilization, and Costs [0.03%]
日本外周T细胞淋巴瘤患者真实世界特征、治疗模式、医疗资源利用及费用分析
Charles Dharmani,Oluwatosin Fofah,Pingping Qu et al.
Charles Dharmani et al.
Background: Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of non-Hodgkin lymphomas associated with aggressive clinical course and suboptimal outcomes. PTCL accounts for a higher proportion of non-...
The Clinical and Economic Value of Incorporating Monocyte Distribution Width Testing in the Detection of Occult Sepsis [0.03%]
单核细胞分布宽度检测在隐性脓毒症中的临床和经济效益评估
Lopamudra Das,Melissa Naiman,Jeff Radcliff et al.
Lopamudra Das et al.
Background: Sepsis is a leading cause of morbidity, mortality, and increased healthcare costs. Early recognition is critical, yet occult sepsis often evades standard screening, delaying care and worsening outcomes. Monocy...
Real-World Treatment Landscape of Individuals with Rett Syndrome Treated and Untreated with Trofinetide in the United States [0.03%]
美国利那新治疗瑞特综合征患者的现实世界治疗现状研究
Nazia Rashid,Vinod K Yakkala,Safiuddin S Syed et al.
Nazia Rashid et al.
Background: Trofinetide (TROF) became the first approved pharmacologic treatment for Rett syndrome (RTT) in the United States in March 2023; however, real-world evidence comparing TROF-treated and untreated individuals is...
Validation of the Medicare-Enhanced Laboratory and Demographics (MELD™) Dataset: A Comprehensive Psychometric, Epidemiologic, and Predictive-Utility Assessment of a 60-Million-Patient Real-World Evidence Resource [0.03%]
验证医疗保险增强型实验室和人口统计学（MELD™）数据集：一项针对包含6亿患者的现实世界证据资源的心理测量、流行病学和预测效用的综合评估
Onur Baser
Onur Baser
Background: Real-world evidence studies increasingly rely on integrated data resources that combine Medicare fee-for-service claims with electronic medical records (EMRs), laboratory results, and patient-reported outcomes...
A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata [0.03%]
Ralicitinib与巴利昔单抗治疗重度斑秃的成本效益分析
Ashley S Cha-Silva,Kate H Zhang,Christopher N Graham et al.
Ashley S Cha-Silva et al.
Background: Ritlecitinib, a JAK3/TEC family kinase inhibitor, and baricitinib, a JAK1/2 inhibitor, are approved for treating severe alopecia areata (AA). ...